Cross-reactivity observed with 1 or more available related molecules.< 50% cross-species reactivity observed with species tested.
Interference observed with 1 or more available related molecules.
This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for human Amyloid beta (aa1-40) has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any Amyloid beta (aa1-40) present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked monoclonal antibody specific for human Amyloid beta (aa1-40) is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Amyloid beta (aa1-40) bound in the initial step. The color development is stopped and the intensity of the color is measured.
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
Cell Culture Supernates, Cerebrospinal Fluid
Average % Recovery
Cell Culture Media (n=4)
Cerebrospinal Fluid (n=4)
To assess linearity of the assay, samples containing and/or spiked with high concentrations of human Amyloid beta were diluted with Diluent RD2-7 to produce samples with values within the dynamic range of the assay.
Preparation and Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: Amyloid beta
Amyloid Precursor Protein (APP) is a type I transmembrane protein that is ubiquitously expressed on cell surfaces. It undergoes complex proteolytic processing and is cleaved by alpha-, beta-, and gamma-Secretases to generate soluble APP alpha, soluble APP beta, and Amyloid beta (A beta) fragments of several lengths. One of these fragments, A beta 42, generated by beta- and gamma-Secretase activities, has been implicated in Alzheimer's disease. Aberrantly high levels of this peptide form and accumulate in the brains of Alzheimer's disease patients to create the senile plaques characteristic of the disease.